Sorry but I like to be specific as between safety and efficacy we know Vascepa is safe, little or no issue. What we need to know is how efficacious is it. We know it met anchor end point which should have gotten us a broader label. But now we must show Vascepa reduces MACE. THAT IS A NEW STORY, BECAUSE ITS ABILITY TO REDUCE TRIGS may not do the job. What we need is that 4 grams of pure EPA improves the EPA/AA ratio enough to reduce inflammation enough to reduce MACE. JELIS suggests so, but we have to prove it on our own population.
Market Data 
Markets 
AI
